



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

Anti-HLA-DR10 [Lym-1] Standard Size Ab03430-2.3

This antibody was created using our proprietary Fc Silent™ engineered Fc domain containing key point mutations that abrogate binding to Fc gamma receptors.

Isotype and Format: Mouse IgG2a, [Fc Silent™](#), Kappa

Clone Number: Lym-1

Alternative Name(s) of Target: CD74; Beta chain HLA-DR; HLA-DR β -chain; β -chain; HLA class II histocompatibility antigen gamma chain; HLA-DR antigens-associated invariant chain; Ia antigen-associated invariant chain; Ii; p33

UniProt Accession Number of Target Protein: P04233

Published Application(s): immunoperoxidase staining;, IP, RIA, WB, FC, IF, IHC

Published Species Reactivity: Human

Immunogen: The original antibody was generated by immunizing mice with tumor cell nuclei preparations as immunogens.

Specificity: This antibody has high affinity for a discontinuous epitope on the β subunit of the human HLA-DR10 surface membrane antigen of malignant B cells, which is not expressed on normal lymphocytes. HLA-DR10 (DR10) is a HLA-DR serotype that recognizes the DRB1*1001 gene product.

Application Notes: This antibody could recognize cell lines of B-cell lineage but not cells of T-cell, myeloid, or erythroid derivation in a live cell radioimmunoassay. Flow cytometric analysis of 22 lymphoma biopsies showed that the majority of B-cell tumors were LYM-1 positive. Approximately 40% of B-cell chronic lymphocytic leukemias were found to be positive with Lym-1. The binding of this antibody to peripheral blot lymphocytes was assessed using indirect immunofluorescence staining. Immunoperoxidase staining of nonlymphoid human organs and tissues revealed weak reactivity of Lym-1. This antibody was also capable of immunoprecipitating HLA-DR10 antigen from Raji cells and ARH-77 myeloma cells. (PMID: 3542194). This antibody also was used for immunohistochemical staining of advanced B-cell NHL tissues from patients (PMID: 10809213). This antibody can be used to identify the HLA-DR variant HLA-DR10 in a western blot (PMID: 8917632). LYM-1 chimeric antigen receptor T cells were demonstrated to exhibit potent anti-tumor effects against B-cell lymphoma (PMID: 29261129).

Antibody First Published in: Epstein et al. Two new monoclonal antibodies, Lym-1 and Lym-2, reactive with human B-lymphocytes and derived tumors, with immunodiagnostic and immunotherapeutic potential. Cancer Res. 1987 Feb 1;47(3):830-40. [PMID:3542194](#)

Note on publication: Describes the immunodiagnostic and immunotherapeutic potential of two monoclonal antibodies reactive with tumor derived human B cell lymphocytes.

Product Form

Size: 200 μ g Purified antibody.

Purification: Protein A affinity purified

Supplied In: PBS with 0.02% Proclin 300.

Storage Recommendation: Store at 4°C for up to 3 months. For longer storage, aliquot and store at -

20°C.

Concentration: 1 mg/ml.

Important note - This product is for research use only. It is not intended for use in therapeutic or diagnostic procedures for humans or animals.